Answers are grounded in this paper and cite their sources.
Background/Objectives: The CYP2D6 gene is critical for the metabolism of numerous clinically used drugs; however, its pharmacogenetic profile in the mestizo population of Peru is poorly characterized, limiting the development of precision medicine strategies tailored to national diversity. We aim to determine the frequency and variability of the CYP2D6*3 and *4 alleles in mestizo populations from Lima and Ayacucho, Peru. Methods: An observational, descriptive, cross-sectional study involving 85 adults from both regions was conducted. Genetic variants were analyzed using real-time PCR (qPCR). Results: At the national level, global allele frequencies were 1.2% for CYP2D6*3 and 8.2% for CYP2D6*4. In Lima, the *3 allele remained in Hardy–Weinberg equilibrium (HWE) (p = 0.886), whereas the *4 allele showed a significant deviation due to an excess of homozygotes (p = 0.005). In Ayacucho, the *4 variant conformed to HWE (p = 0.645). The frequency of *3 is similar to that of European populations and higher than that of populations of African and Asian origin; in contrast, *4 aligned with African and Asian ranges, being notably lower than the European average. Based exclusively on the two interrogated variants, 83.53% of participants carried neither CYP2D6*3 nor *4, 14.12% were heterozygous for one of these no-function variants, and 2.35% were homozygous for CYP2D6*4. Because the genotyping strategy did not interrogate other clinically relevant CYP2D6 alleles or structural variants, complete star-allele diplotypes, activity scores, and metabolizer phenotypes could not be reliably assigned. Conclusions: A low overall frequency and a geographically differential distribution of the null-function alleles CYP2D6*3 and *4 were observed in mestizo populations from Lima and Ayacucho, underscoring the need for a broader regional characterization of CYP2D6 variability in Peru. Since only two null-function alleles were analyzed, these findings represent preliminary pharmacogenetic data and should not be used to infer complete diplotypes, activity scores, or metabolic phenotypes.
No takes yet. Share an insight, caveat, or question.
Alvarado et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: